Compare Natera Inc. Common Stock (NTRA) vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF (VTIP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Vanguard Sht-Term Inflation-Protected Sec Idx ETF — how do they compare? Natera Inc. Common Stock trades at $394 (market cap $57.03B), while Vanguard Sht-Term Inflation-Protected Sec Idx ETF trades at $48.96 (market cap $73.20B). The key difference: Vanguard Sht-Term Inflation-Protected Sec Idx ETF is the larger of the two by market cap, and Natera Inc. Common Stock is trading nearer its 52-week high, Vanguard Sht-Term Inflation-Protected Sec Idx ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Vanguard Sht-Term Inflation-Protected Sec Idx ETF for 92 Days on average.
| NTRA | VTIP | |
|---|---|---|
Market Cap | $57.03B | $73.20B |
Volume | 1,131,157 | 2,410,205 |
Sector | Health | — |
52-Week High | $425.64 | $50.46 |
52-Week Low | $179.42 | $48.38 |
Typical Hold Time | 0 Days | 92 Days |
Enterprise Value | $56.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
VTIP, a Vanguard short-term inflation-protected securities ETF, trades at $48.46, down 0.06% on the day. Technical indicators show a bearish trend with moving averages signaling sell pressure, while oscillators are neutral. The fund focuses on short-duration TIPS to hedge inflation with minimal interest-rate risk, attracting institutional interest as seen in recent filings. News highlights its role in protecting against inflation spikes and Fed rate hikes.
The outlook for VTIP is supported by persistent inflation and high real yields, offering a defensive allocation. Risks include interest rate volatility and potential underperformance if inflation recedes. Institutional accumulation suggests confidence, but investors should weigh the fund's low sensitivity against broader bond market shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Vanguard Sht-Term Inflation-Protected Sec Idx ETF
The index is a market-capitalization-weighted index that includes all inflation-protected public obligations issued by the US Treasury with remaining maturities of less than 5 years. The advisor attempts to replicate the target index by investing all, or substantially all, of its assets in the securities that make up the index, holding each security in approximately the same proportion as its weighting in the index.
Read more on VTIP →
